• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

c-Myc 通过下调尿激酶(uPA)及其受体来调节细胞迁移和存活。

Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor.

机构信息

Institute of Genetics and Biophysics Adriano Buzzati-Traverso, Consiglio Nazionale delle Ricerche (CNR), Via P. Castellino 111, 80131 Naples, Italy.

出版信息

Mol Cell Biol. 2010 Apr;30(7):1838-51. doi: 10.1128/MCB.01442-09. Epub 2010 Feb 1.

DOI:10.1128/MCB.01442-09
PMID:20123981
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2838082/
Abstract

It has been proposed that c-Myc proapoptotic activity accounts for most of its restraint of tumor formation. We established a telomerase-immortalized human epithelial cell line expressing an activatable c-Myc protein. We found that c-Myc activation induces, in addition to increased sensitivity to apoptosis, reductions in cell motility and invasiveness. Transcriptome analysis revealed that urokinase (uPA) and uPA receptor (uPAR) were strongly downregulated by c-Myc. Evidence is provided that the repression of uPA and uPAR may account for most of the antimigratory and proapoptotic activities of c-Myc. c-Myc is known to cooperate with Ras in cellular transformation. We therefore investigated if this cooperation could converge in the control of uPA/uPAR expression. We found that Ras is able to block the effects of c-Myc activation on apoptosis and cellular motility but not on cell invasiveness. Accordingly, the activation of c-Myc in the context of Ras expression had only minor influence on uPAR expression but still had a profound repressive effect on uPA expression. Thus, the differential regulation of uPA and uPAR by c-Myc and Ras correlates with the effects of these two oncoproteins on cell motility, invasiveness, and survival. In conclusion, we have discovered a novel link between c-Myc and uPA/uPAR. We propose that reductions of cell motility and invasiveness could contribute to the inhibition of tumorigenesis by c-Myc and that the regulation of uPA and uPAR expression may be a component of the ability of c-Myc to reduce motility and invasiveness.

摘要

有人提出,c-Myc 的促凋亡活性解释了其对肿瘤形成的大部分抑制作用。我们建立了一个端粒酶永生化的人上皮细胞系,表达一种可激活的 c-Myc 蛋白。我们发现,c-Myc 的激活除了增加细胞对凋亡的敏感性外,还降低了细胞的迁移和侵袭能力。转录组分析显示,尿激酶 (uPA) 和 uPA 受体 (uPAR) 被 c-Myc 强烈下调。有证据表明,uPA 和 uPAR 的抑制可能解释了 c-Myc 的大部分抗迁移和促凋亡活性。众所周知,c-Myc 与 Ras 协同作用于细胞转化。因此,我们研究了这种协同作用是否可以集中在 uPA/uPAR 表达的控制上。我们发现 Ras 能够阻断 c-Myc 激活对细胞凋亡和细胞迁移的影响,但不能阻断对细胞侵袭的影响。因此,在 Ras 表达的背景下激活 c-Myc 对 uPAR 表达只有轻微的影响,但对 uPA 表达仍有显著的抑制作用。因此,c-Myc 和 Ras 对 uPA 和 uPAR 的不同调节与这两种癌蛋白对细胞迁移、侵袭和存活的影响相关。总之,我们发现了 c-Myc 和 uPA/uPAR 之间的一个新联系。我们提出,细胞迁移和侵袭的减少可能有助于 c-Myc 抑制肿瘤发生,而 uPA 和 uPAR 表达的调节可能是 c-Myc 降低迁移和侵袭能力的一个组成部分。

相似文献

1
Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor.c-Myc 通过下调尿激酶(uPA)及其受体来调节细胞迁移和存活。
Mol Cell Biol. 2010 Apr;30(7):1838-51. doi: 10.1128/MCB.01442-09. Epub 2010 Feb 1.
2
siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.小干扰RNA介导的尿激酶型纤溶酶原激活剂及其受体的同时下调抑制乳腺癌细胞的血管生成、侵袭并引发细胞凋亡。
Int J Oncol. 2006 Apr;28(4):831-9.
3
Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.尿激酶型纤溶酶原激活物及其受体轴的激活对于前列腺癌小鼠模型中巨噬细胞浸润是必不可少的。
Neoplasia. 2011 Jan;13(1):23-30. doi: 10.1593/neo.10728.
4
Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.3,3'-二吲哚甲烷下调 uPA 和 uPAR,从而抑制乳腺癌细胞的生长和迁移。
J Cell Biochem. 2009 Nov 1;108(4):916-25. doi: 10.1002/jcb.22323.
5
Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration.3,3'-二吲哚甲烷(DIM)使尿激酶型纤溶酶原激活剂(uPA)及其受体(uPAR)失活,从而抑制前列腺癌细胞的生长和迁移。
J Cell Biochem. 2009 Jun 1;107(3):516-27. doi: 10.1002/jcb.22152.
6
Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching.尿激酶和尿激酶受体参与神经元迁移、轴突生长和分支的调节。
Eur J Cell Biol. 2016 Sep;95(9):295-310. doi: 10.1016/j.ejcb.2016.05.003. Epub 2016 Jun 3.
7
Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo.uPA、uPAR 和组织蛋白酶 B 的 si-RNA 双顺反子构建体在体外和体内均抑制脑膜瘤中 p53 的致癌作用。
Int J Oncol. 2011 Apr;38(4):973-83. doi: 10.3892/ijo.2011.934. Epub 2011 Feb 2.
8
TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.TGF-β2 通过介导尿激酶型纤溶酶原激活物(uPA)的表达促进 RPE 细胞向胶原凝胶内浸润。
Exp Eye Res. 2013 Oct;115:13-21. doi: 10.1016/j.exer.2013.06.020. Epub 2013 Jun 28.
9
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.尿激酶型纤溶酶原激活物/尿激酶型纤溶酶原激活物受体和 maspin 在口腔鳞状细胞癌中的表达:与浸润方式和临床病理因素的关系。
Oncol Rep. 2011 Dec;26(6):1555-60. doi: 10.3892/or.2011.1419. Epub 2011 Aug 10.
10
Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.下调 uPA/uPAR 抑制间断低氧诱导的 DAOY 和 D283 髓母细胞瘤细胞上皮间质转化(EMT)。
Int J Oncol. 2011 Mar;38(3):733-44. doi: 10.3892/ijo.2010.883. Epub 2010 Dec 22.

引用本文的文献

1
Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology.靶向MYC:肿瘤学中的多维调控与治疗策略
Genes Dis. 2024 Sep 16;12(4):101435. doi: 10.1016/j.gendis.2024.101435. eCollection 2025 Jul.
2
Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs.利用癌症驱动基因重新绘制尿激酶受体(uPAR)信号通路以探索潜在的抗癌靶点和药物。
Pharmaceuticals (Basel). 2023 Oct 9;16(10):1435. doi: 10.3390/ph16101435.
3
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.MYC 癌基因:天然产物治疗癌症的可用药靶。
Aging Dis. 2024 Apr 1;15(2):640-697. doi: 10.14336/AD.2023.0520.
4
Central gene transcriptional regulatory networks shaping monocyte development in bone marrow.骨髓中塑造单核细胞发育的中枢基因转录调控网络。
Front Immunol. 2022 Oct 11;13:1011279. doi: 10.3389/fimmu.2022.1011279. eCollection 2022.
5
S146L in MYC is a context-dependent activating substitution in cancer development.MYC 中的 S146L 是一种与癌症发展相关的、具有上下文依赖性的激活性替换。
PLoS One. 2022 Aug 26;17(8):e0272771. doi: 10.1371/journal.pone.0272771. eCollection 2022.
6
Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA.通过抑制尿激酶型纤溶酶原激活剂提高载槲皮素聚合物纳米粒对三阴性乳腺癌的治疗效果。
RSC Adv. 2020 Sep 17;10(57):34517-34526. doi: 10.1039/d0ra04231e. eCollection 2020 Sep 16.
7
Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.尿激酶受体信号传导对细胞功能的调节:一种机制性观点
Front Cell Dev Biol. 2022 Apr 8;10:818616. doi: 10.3389/fcell.2022.818616. eCollection 2022.
8
CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.CRISPR/Cas9介导的uPAR基因敲除导致黑色素瘤和结肠癌细胞系中的肿瘤生长抑制、表皮生长因子受体(EGFR)下调以及干性标志物的诱导。
Front Oncol. 2021 May 14;11:663225. doi: 10.3389/fonc.2021.663225. eCollection 2021.
9
Prognostic significance of uPA and uPAR expression in patients with cervical cancer undergoing radiotherapy.uPA和uPAR表达在接受放疗的宫颈癌患者中的预后意义
Oncol Lett. 2021 May;21(5):423. doi: 10.3892/ol.2021.12684. Epub 2021 Mar 29.
10
Mi-RNA-888-5p Is Involved in S-Adenosylmethionine Antitumor Effects in Laryngeal Squamous Cancer Cells.微小RNA-888-5p参与S-腺苷甲硫氨酸对喉鳞状癌细胞的抗肿瘤作用。
Cancers (Basel). 2020 Dec 7;12(12):3665. doi: 10.3390/cancers12123665.

本文引用的文献

1
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.一种与基质相关的基因特征可预测乳腺癌对新辅助化疗的耐药性。
Nat Med. 2009 Jan;15(1):68-74. doi: 10.1038/nm.1908. Epub 2009 Jan 4.
2
Myc's broad reach.Myc的广泛影响范围。
Genes Dev. 2008 Oct 15;22(20):2755-66. doi: 10.1101/gad.1712408.
3
Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation.
Int J Cancer. 2009 Jan 15;124(2):316-25. doi: 10.1002/ijc.23933.
4
Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.癌基因MYCN调节神经母细胞瘤中NKT细胞向疾病部位的定位。
J Clin Invest. 2007 Sep;117(9):2702-12. doi: 10.1172/JCI30751.
5
Novel c-MYC target genes mediate differential effects on cell proliferation and migration.新型c-MYC靶基因对细胞增殖和迁移具有不同的调控作用。
EMBO Rep. 2007 Jan;8(1):70-6. doi: 10.1038/sj.embor.7400849. Epub 2006 Dec 8.
6
The c-Myc target gene network.c-Myc靶基因网络。
Semin Cancer Biol. 2006 Aug;16(4):253-64. doi: 10.1016/j.semcancer.2006.07.014. Epub 2006 Jul 25.
7
Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels.尿激酶通过其受体发出的信号,通过提高BCL-xL表达水平来保护细胞免受失巢凋亡。
J Biol Chem. 2006 Jun 30;281(26):17758-67. doi: 10.1074/jbc.M601812200. Epub 2006 Apr 21.
8
Targeting of Miz-1 is essential for Myc-mediated apoptosis.靶向Miz-1对于Myc介导的细胞凋亡至关重要。
J Biol Chem. 2006 Feb 10;281(6):3283-9. doi: 10.1074/jbc.M513038200. Epub 2005 Dec 13.
9
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.人类癌症中的致癌途径特征作为靶向治疗的指导
Nature. 2006 Jan 19;439(7074):353-7. doi: 10.1038/nature04296. Epub 2005 Nov 6.
10
Myc represses transcription through recruitment of DNA methyltransferase corepressor.Myc 通过招募 DNA 甲基转移酶共抑制因子来抑制转录。
EMBO J. 2005 Jan 26;24(2):336-46. doi: 10.1038/sj.emboj.7600509. Epub 2004 Dec 16.